Video

Patient Profile: A 67-Year-Old Man with mCRPC and Asymptomatic Bone Metastases

Author(s):

Andrew J. Armstrong, MD,Matthew Manning, MD

Centering discussion on a patient profile of mCRPC with asymptomatic bone metastases, experts share best approaches to treating and optimizing outcomes for such patients, including supplement recommendations to prevent bone fractures.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments
Video

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Apr 23rd 2025 - Apr 24th 2026

online-activity
View More
Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2
Video

Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2

Apr 23rd 2025 - Apr 24th 2026

online-activity
View More
Addressing Unmet Needs in HER2+ Metastatic BTC
Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 18th 2025 - Apr 19th 2026

online-activity
View More
Related Content
Mark D. Tyson, II, MD, MPH
April 24th 2025

Oncology Experts Preview Top Abstracts From AUA 2025

Neeraj Agarwal, MD
July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

Nataliya Mar, MD
April 21st 2025

Broader ARPI Arsenal Enables Personalized, Cost-Conscious Treatment Selection in Prostate Cancer

Andrew J. Armstrong, MD, MSc
June 15th 2023

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

Evan Y. Yu, MD
April 18th 2025

Investigational and Established Biomarkers Guide Ongoing CRPC Therapy Developments

Marc R. Matrana, MD
April 17th 2025

Talazoparib/Enzalutamide Combo, Radioligand Therapy Expand Options in mCRPC